Submission of audited financial results for the quarter and year ended 31 March, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.5 pts less than Nifty Microcap 250 and 4.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Astal Laboratories Ltd (formerly Macro International Ltd) submitted audited standalone results for Q4 FY25 and full year ended 31 March 2025. Full-year revenue from operations jumped to Rs. 6,423.10 lakhs from Rs. 2,364.77 lakhs in FY24, a growth of about 172%. Profit after tax for FY25 climbed to Rs. 892.53 lakhs versus Rs. 78.47 lakhs in FY24, with corresponding EPS rising to Rs. 9.08 from Rs. 1.55. Q4 FY25 standalone revenue stood at Rs. 2,346.67 lakhs with PAT of Rs. 274.48 lakhs. The auditor Sathuluri & Co. issued an unmodified (clean) opinion on the results. The company operates in a single segment — manufacturing and trading of active pharmaceutical ingredients (bulk drugs).
Strong double-digit top-line and bottom-line growth is a positive signal for shareholders, but the company reported negative operating cash flow of Rs. (1,251.73) lakhs for FY25 with sharp rises in inventories and trade receivables, indicating working-capital strain despite the accounting profit. Investors should weigh earnings quality alongside growth before drawing conclusions.